Determination of milnacipran, a serotonin and noradrenaline reuptake inhibitor, in human plasma using liquid chromatography with spectrofluorimetric detection.

[1]  Thomas Layloff,et al.  Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies , 1992, Pharmaceutical Research.

[2]  C. Palmier,et al.  Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran , 2004, European Journal of Clinical Pharmacology.

[3]  M. Briley,et al.  Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride (F 2207), a new potential antidepressant , 2004, Psychopharmacology.

[4]  A. Al-majed,et al.  Spectrofluorimetric determination of vigabatrin and gabapentin in urine and dosage forms through derivatization with fluorescamine. , 2002, Journal of pharmaceutical and biomedical analysis.

[5]  S. Montgomery,et al.  Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability , 1997, International clinical psychopharmacology.

[6]  B. Leonard,et al.  Pharmacokinetics of milnacipran in comparison with other antidepressants , 1996, International clinical psychopharmacology.

[7]  C. Palmier,et al.  Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat , 1992, Neuropharmacology.

[8]  M. Briley,et al.  1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants. , 1987, Journal of medicinal chemistry.

[9]  S. Udenfriend,et al.  Studies on the reaction of fluorescamine with primary amines. , 1974, Archives of biochemistry and biophysics.

[10]  S. Udenfriend,et al.  Amino acid analysis with fluorescamine at the picomole level. , 1973, Archives of biochemistry and biophysics.